Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023

被引：0

作者：

Scheck, Magdalena K. ^{[1
]}

Ekmekciu, Ira ^{[2
]}

Sommerhaeuser, Greta ^{[3
,4
,5
]}

Heise, Christian ^{[6
]}

Mavroeidi, Ilektra Antonia ^{[7
]}

Kunzmann, Volker ^{[8
]}

Wege, Henning ^{[9
]}

Reinacher-Schick, Anke ^{[2
]}

Hofheinz, Ralf-Dieter ^{[10
]}

Oliver Goetze, Thorsten ^{[11
]}

Lorenzen, Sylvie ^{[1
]}

Nieto, Alexander Edward ^{[1
]}

机构：

[1] Tech Univ Munich, Dept Med Hematol & Oncol 3, Klinikum Rechts Isar, Munich, Germany

[2] Ruhr Univ Bochum, St Josef Hosp, Dept Hematol Oncol & Palliat Care, Bochum, Germany

[3] Charite Univ Med Berlin, Berlin, Germany

[4] Free Univ Berlin, Berlin, Germany

[5] Humboldt Univ, Dept Hematol Oncol & Canc Immunol CVK CCM, Berlin, Germany

[6] Univ Hosp Heidelberg, Clin Internal Med Gastroenterol Infect Dis & Poiso, Heidelberg, Germany

[7] Univ Hosp Essen, Dept Med Oncol, Essen, Germany

[8] Univ Hosp Wurzburg, Clin Internal Med 2, Wurzburg, Germany

[9] Klinikum Esslingen, Dept Internal Med Oncol Hematol Gastroenterol & In, Esslingen, Germany

[10] Univ Hosp Mannheim, Mannheim, Germany

[11] Frankfurt Inst Clin Canc Res, Frankfurt, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷 / 05期

关键词：

PEMBROLIZUMAB PLUS CHEMOTHERAPY; ESOPHAGEAL CANCER; JUNCTION; CHEMORADIOTHERAPY; SURGERY; ADENOCARCINOMA; KEYNOTE-859; TRIAL;

D O I：

10.1159/000538324

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：224 / 228

页数：5

共 27 条

[1] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Ajani, J. A.
Lordick, F.
Bang, Y-J.
Enzinger, P. C.
Ilson, D. H.
Shah, M. A.
Van Cutsem, E.
Xu, R-H.
Aprile, G.
Xu, J.
Cid, R. A. Pazo
Kang, Y-K.
Yang, J.
Moran, D.
Bhattacharya, P.
Matsangou, M.
Arozullah, A.
Park, J. W.
Shitara, K.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1322 - S1322
[2] Al-Batran SE, 2023, J CLIN ONCOL, V41
[3] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Yung-Jue
Van Cutsem, Eric
Feyereislova, Andrea
Chung, Hyun C.
Shen, Lin
Sawaki, Akira
Lordick, Florian
Ohtsu, Atsushi
Omuro, Yasushi
Satoh, Taroh
Aprile, Giuseppe
Kulikov, Evgeny
Hill, Julie
Lehle, Michaela
Ruschoff, Josef
Kang, Yoon-Koo
[J]. LANCET, 2010, 376 (9742) : 687 - 697
[4] Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
Eyck, Ben M.
van Lanschot, J. Jan B.
Hulshof, Maarten C. C. M.
van der Wilk, Berend J.
Shapiro, Joel
van Hagen, Pieter
Henegouwen, Mark I. van Berge
Wijnhoven, Bas P. L.
van Laarhoven, Hanneke W. M.
Nieuwenhuijzen, Grard A. P.
Hospers, Geke A. P.
Bonenkamp, Johannes J.
Cuesta, Miguel A.
Blaisse, Reinoud J. B.
Busch, Olivier R.
Creemers, Geert-Jan M.
Punt, Cornelis J. A.
Plukker, John Th M.
Verheul, Henk M. W.
Bilgen, Ernst J. Spillenaar
van der Sangen, Maurice J. C.
Rozema, Tom
Ten Kate, Fiebo J. W.
Beukema, Jannet C.
Piet, Anna H. M.
van Rij, Caroline M.
Reinders, Janny G.
Tilanus, Hugo W.
Steyerberg, Ewout W.
van der Gaast, Ate
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) : 1995 - +
[5] Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Janjigian, Y. Y.
Al-Batran, S-E.
Wainberg, Z. A.
Van Cutsem, E.
Molena, D.
Muro, K.
Hyung, W. J.
Wyrwicz, L. S.
Oh, D. Y.
Omori, T.
Moehler, M.
Garrido, M.
Oliveira, S. Cunha Sousa
Liberman, M.
Oliden, V. Castro
Bilici, M.
Kurland, J. F.
Xynos, I.
Mann, H.
Tabernero, J.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1315 - S1316
[6] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus
Garrido, Marcelo
Salman, Pamela
Shen, Lin
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda Campos
Liu, Tianshu
Schenker, Michael
Yanez, Patricio
Tehfe, Mustapha
Kowalyszyn, Ruben
Karamouzis, Michalis V.
Bruges, Ricardo
Zander, Thomas
Pazo-Cid, Roberto
Hitre, Erika
Feeney, Kynan
Cleary, James M.
Poulart, Valerie
Cullen, Dana
Lei, Ming
Xiao, Hong
Kondo, Kaoru
Li, Mingshun
Ajani, Jaffer A.
[J]. LANCET, 2021, 398 (10294) : 27 - 40
[7] Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
Kubota, Y.
Kawazoe, A.
Mishima, S.
Nakamura, Y.
Kotani, D.
Kuboki, Y.
Bando, H.
Kojima, T.
Doi, T.
Yoshino, T.
Kuwata, T.
Shitara, K.
[J]. ESMO OPEN, 2023, 8 (01)
[8] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Lordick, F.
Shah, M. A.
Shitara, K.
Ajani, J. A.
Bang, Y-J.
Enzinger, P. C.
Ilson, D. H.
Van Cutsem, E.
Plazas, J. Gallego
Huang, J.
Shen, L.
Oh, S. C.
Sunpaweravong, P.
Soo, H. H. F.
Turk, H. M.
Park, J. W.
Moran, D.
Bhattacharya, P.
Cao, Y. J.
Xu, R-H.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1321 - S1321
[9] Lorenzen S., J Clin Oncol, V2023, pJco2300975
[10] Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?
Markar, Sheraz
Gronnier, Caroline
Duhamel, Alain
Pasquer, Arnaud
Thereaux, Jeremie
du Rieu, Mael Chalret
Lefevre, Jeremie H.
Turner, Kathleen
Luc, Guillaume
Mariette, Christophe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) : 3866 - +

← 1 2 3 →